Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial

Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial

Abstract Background Efficacy and tolerance of anakinra (ANK) in the treatment of giant cell arteritis (GCA) need to be assessed. Methods This phase 3 study (NCT02902731) was a prospective multicenter, randomized, double-blind, placebo-controlled trial conducted over a 52-week period. GCA patients we...

Full description

Saved in:
Bibliographic Details
Main Authors: Hubert de Boysson, Kim Heang Ly, Loïk Geffray, Thomas Quemeneur, Eric Liozon, Holy Bezanahary, Noémie Le Gouellec, Alexandra Audemard, Anael Dumont, Samuel Deshayes, Jonathan Boutemy, Gwénola Maigné, Nicolas Martin Silva, Audrey Sultan, Brigitte Le Mauff, Gauthier Petit, Jean-Jacques Parienti, Achille Aouba
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Arthritis Research & Therapy
Subjects:
Giant cell arteritis
Anakinra
Glucocorticoids
Interleukin-1
Quality of life
Online Access:https://doi.org/10.1186/s13075-025-03493-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13075-025-03493-z

Similar Items